期刊文献+

血液灌流串联血液透析对血清甲状旁腺激素的影响 被引量:1

Effect of connecting hemoperfusion with hemodialysis on serum parathyroid hormone
下载PDF
导出
摘要 目的:研究血液透析与血液透析串联血液灌流清除血清甲状旁腺激素(PTH)的效果。方法:将32例维持性血液透析患者随机分为两组:血液透析组(HD)、血液灌流+血液透析组(HP+HD)。比较两组单次治疗对血清PTH的清除率。结果:两组治疗后PTH均有所下降,P值均小于0.05;治疗后HP+HD组较HD组下降明显(P<0.05)。结论:HP+HD能比HD更有效清除PTH。 Objective:To observe the effects of connecting hemoperfusion with hemodialysis on clearance of serum parathyroid hormone(PTH).Methods:Thirty-two hemodialysis patients were randomized into group of hemodialysis(HD) or hemoperfusion+hemodialysis(HP+HD)for comparing the clearance rate of serum PTH in a single treatment.Results:PTH dropped in the two groups(P0.05),whereas the level of PTH were decreased more obvious in HP+HD group.Conclusion: HP+HD can be more effective in removing PTH than HD.
作者 吴军 王艺
出处 《皖南医学院学报》 CAS 2010年第5期367-368,共2页 Journal of Wannan Medical College
关键词 血液透析 血液灌流 甲状旁腺激素 hemodialysis hemoperfusion parathyroid hormone(PTH)
  • 相关文献

参考文献6

  • 1美国NKF-K/DOQI工作组.慢性肾脏病及透析的临床实践指南Ⅱ[M].第1版.北京:人民卫生出版社,2005:306-307.
  • 2BLOCK GA,KLASSEN PS,LAZARUS JM,et al.Mineralmetabolism,mortality,and mobidity in maintenancehemodialysis[J].J Am Soc Nephrol,2004,15:2208-2218.
  • 3BLOCK GA,PORT FK.Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients:recommendations for a change inmanagement[J].Am J Kidney Dis,2000,35(1):1226-1237.
  • 4MARIA PAZ MARCO,LOURDES SRAVER,ANGELS BETRIU,et al.Higher impact of mineral metabolism oncardiovascular mortality in a European hemodialysispopulation[J].Kidney Int,2003,63(Suppl 85):S111-114.
  • 5高原,王莉华,马慧鹏,王丽丽,高志英.血液透析血液灌流对继发甲状旁腺功能亢进的影响[J].中国实用内科杂志:临床前沿版,2006,26(5):758-760. 被引量:16
  • 6水润芝.血液灌流加血液透析抢救急性重症药物、毒物中毒109例分析[J].皖南医学院学报,2005,24(4):295-296. 被引量:2

二级参考文献16

  • 1陈恩静 甘华 等.血液灌流串联血液透析抢救急性中毒的临床应用[J].中国急救医学,2001,12(4):239-239.
  • 2汤伟光 李忠林 等.血液透析串联血液灌流抢救急性重度中毒患者30例临床体会[J].中华肾脏病杂志,2001,17(1):15-15.
  • 3Klassen PS,Lawrin G,Reddan DN,et al.Association between pulse pressure and morta1ity in patients undergoing maintenance hemodialysis[].The Journal of The American Medical Association.2002
  • 4Block GA,Port FK.Re-evaluation of risks associated with hy-perphosphatemia and hyperparathyroidsm in dialysis patients:Recommendations for a change in management[].American Journal of Kidney Diseases.2000
  • 5Dubel JR,Milford EL.The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemo-dialysis population[].American Journal of Kidney Diseases.2003
  • 6Duerin AP,London GM,Marchais SJ,et al.Arterial stiffening and vascular calcifications in end-stage renal disease[].Nephrology Dialysis Transplantation.2000
  • 7TzannoMartins C,Futata E,Jorgetti V,et al.Immune re-sponse in hemodialysis patients:is there any difference when low and high iPTH levels are compared?[].Clinical Nephrology.2000
  • 8Ganesh SK,Stack AG,Levin NW,et al.Association of elevat-ed serum P04,Cax P04product,and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients[].JAS-NL.2001
  • 9Fuarles LD,Sherrard DJ,Adler S,et al.The calcimimetic AMG073as a potential treatment for secondary hyperparathyroid-ism of end-stage renal disease[].Journal of the American Society of Nephrology.2003
  • 10Blacher J,Guerin AP,Pannier B,et al.Arterial calcifications,arterial stiffness,and cariovascular risk in end-stage renal dis-ease[].Journal of Hypertension.2001

共引文献15

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部